THERAPIX BIOSCI/S ADR TRPX said Tuesday that it has signed a letter of intent for a merger with the Canadian cannabis company Destiny Biosciences.
The deal is a stock-for-stock transaction valuing Therapix at about $48 million plus cash on hand at closing. The deal values the combined company at about $151 million, Therapix said.
The Israeli cannabinoid pharmaceutical company said it expects a definitive agreement to be struck in the third quarter of this year; upon closing, Therapix equity holders are anticipated to hold about 32% of the combined company.
Benzinga's Cannabis Capital Conference heads to Detroit on Aug. 15 — click here to learn more!
"Combining the two companies creates a unique patented and valuable opportunity to create unique and very specific cannabis-based medicinal formulations literally from seed to sale, and the companies have already identified and commenced work in immediate areas of interest," according to Therapix.
The stock was trading higher by 71.3% at $3.94 at the time of publication Tuesday. The stock has a 52-week high of $9.30 and a 52-week low of $2.22.
Never miss a news story in the cannabis world. Click here to check out Benzinga Cannabis for more.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving – don’t get left behind!
Curious about what’s next for the industry and how to leverage California’s unique market?
Join top executives, policymakers, and investors at the Benzinga Cannabis Market Spotlight in Anaheim, CA, at the House of Blues on November 12. Dive deep into the latest strategies, investment trends, and brand insights that are shaping the future of cannabis!
Get your tickets now to secure your spot and avoid last-minute price hikes.